PUBBLICATO IL NUOVO NUMERO DELLA WHO PHARMACEUTICAL NEWSLETTER

Fonte: WHO. N 1, dicembre 2017

E' disponibile il nuovo numero della WHO Pharmaceutical newsletter.

In questo numero:

REGULATORY MATTERS
• Amiodarone (intravenous)
• Bisphosphonates (intravenous)
• Bupropion and varenicline
• Cajeput Oil (Melaleuca leucodendran)
• Cobicistat, ritonavir and corticosteroid metabolised by CYP3A
• Codeine-containing products
• Combined hormonal contraceptives
• Direct-acting antivirals for hepatitis C treatment
• Duloxetine, venlafaxine and milnacipran
• Fluoroquinolones
• General anaesthetic and sedation drugs
• Idelalisib
• Iguratimod
• Interferon beta-1b
• Intravenous N-acetylcysteine (NAC) for paracetamol overdose
• Lenalidomide
• Levetiracetam
• Oral isotretinoin
• Pioglitazone-containing medicines
• Riociguat
• Risperidone

SAFETY OF MEDICINE
• Adrenaline autoinjectors
• Antidepressants
• Apremilast
• Carbamazepine
• Direct-acting antivirals to treat chronic hepatitis C
• Phenylephrine and acetaminophen
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Sodium bicarbonate

SIGNAL
• Chymotrypsin and anaphylactic shock, a continuing safety issue
• Ganciclovir and hypoglycaemia
• Lamivudine and hearing decreased

FEATURE
• Introduction of an electronic system for reporting adverse drug reactions in Tanzania
• Third WHO Asia Pacific Pharmacovigilance Training Course
• Recommendations from the 39th Annual Meeting of Representatives of the National Pharmacovigilance Centres participating in the WHO Programme for International Drug Monitoring